Nektar Therapeutics | NKTR - Operating Expenses


Nektar Therapeutics reported $49.12M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Amgen USD 5.69B 6B Sep/2026
Baxter International USD 6.5B 3.82B Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Cipla INR 63.61B 1.3B Sep/2026
Dr.Reddys Laboratories INR 74.82B 2.93B Sep/2026
Eisai JPY 209.6B 6.14B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 390.27M 10M Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Novartis USD 9.88B 325M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Takeda JPY 981.78B 36.71B Sep/2026
Teva Pharmaceutical Industries USD 3.18B 733M Sep/2026
Xencor USD 87.82M 5.44M Jun/2026